A Phase III randomized double-blind, controlled study of ICT 107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy
Autologous dendritic cells charged with peptides derived from tumor-associated antigens to drive the formation of T cells that specifically target cancer stem cells
Randomized, double-blind study.
Registration-enabling Phase 3 trial. Safety. Efficacy - overall survival.
This study has suspended participant recruitment.